<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01408563</url>
  </required_header>
  <id_info>
    <org_study_id>11-085</org_study_id>
    <nct_id>NCT01408563</nct_id>
  </id_info>
  <brief_title>Reduced Intensity Double Umbilical Cord Blood Transplantation</brief_title>
  <official_title>A Phase II Study of Reduced Intensity Double Umbilical Cord Blood Transplantation Using Fludarabine, Melphalan, and Low Dose Total Body Radiation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will use two cord blood units for transplantation using a reduced intensity
      regimen rather than using intense doses of chemotherapy and radiation therapy. Two cord blood
      units (double cord blood) are being used, as the numbers of blood cells in one unit are too
      few to allow successful growth of these cells.

      Because the risk of infection, particularly virus infection, is high after double cord blood
      transplant, this study seeks to reduce the rise of virus infection by using a reduced
      intensity regimen without a medicine called antithymocyte globulin (ATG), as used in prior
      cord blood transplants. Subjects will receive two chemotherapy drugs, melphalan and
      fludarabine, and low dose of total body radiation (one treatment) instead of the ATG. The
      number of patients with virus infections in this study will be compared to our prior
      experience using the ATG.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will receive their transplants as in-patients.

        -  IV-Catheter

             -  one or two IV catheters will be placed on the day of hospital admission

        -  Conditioning

             -  Fludarabine IV six days before transplant (days -7, -6, -5. -4, -3, -2)

             -  Melphalan IV (day -1)

             -  Total body radiation on day 0 (same day as transplant)

        -  Immunosuppressive Therapy

             -  Tacrolimus and sirolimus beginning day -3, daily for 6-9 months post-transplant.
                Given IV as in-patient, orally as out-patient

        -  Infusion of Cord Blood units

             -  2 cord blood units IV on Day 0 Routine post-transplant supportive care will be
                provided
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">June 2017</completion_date>
  <primary_completion_date type="Actual">June 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With a Clinically Significant Infection</measure>
    <time_frame>1 Year</time_frame>
    <description>The one year significant infection rate (infections requiring medical intervention) after double umbilical cord blood transplant using a novel conditioning regimen of fludarabine/melphalan/low dose total body radiation. The data is shown as the number of significant infections participants experienced during the first year, measured from the start of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median Time to Neutrophil Engraftment</measure>
    <time_frame>From the time of transplantation, until the time of neutrophil engraftment, median duration of 24 days</time_frame>
    <description>The median number of days measured from the time of transplantation, until the first documented neutrophil engraftment. neutrophil engraftment is defined as the first of 3 consecutive days of absolute neutrophil count &gt; 500 neutrophils per microliter of blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Time to Platelet Engraftment</measure>
    <time_frame>From the time of transplantation, until the time of platelet engraftment, median duration of 52 days</time_frame>
    <description>The time to platelet engraftment is measured from the time of transplantation until the time of first documented platelet engraftment. Platelet engraftment is defined as a platelet count ≥ 20,000/µL for three consecutive measurements over three or more days. The first of the three days will be designated the day of platelet engraftment. Subjects must not have had platelet transfusions during the preceding 3 days or in the following 7 days after the day of engraftment, unless the platelet transfusion is being given specifically to achieve a platelet threshold to allow an elective invasive procedure, such as a central catheter removal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Primary Graft Failure</measure>
    <time_frame>From the time of transplantation until 42 days post transplantation</time_frame>
    <description>Primary graft failure is defined as the failure to achieve an absolute neutrophil count (ANC) &gt;500/ µL by day 42, in the absence of relapse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of Grade II-IV and Grade III-IV Acute Graft Versus Host Disease (GVHD) at 100 Days</measure>
    <time_frame>100 Days</time_frame>
    <description>Acute GVHD is assessed using Consensus Criteria:
Organ Classifications:
0: No rash due to GVHD; Bilirubin &lt; 2 mg/dL; &lt; 500 mL diarrhea/ day
1: Maculopapular rash &lt; 25% of body surface; Bilirubin 2-3 mg/dL; 500 to 999 mL diarrhea/ day or persistent nausea with histologic evidence of GVHD in stomach/ duodenum
2: Maculopapular rash 25-50% of body surface; Bilirubin 3.1-6 mg/dL; 1,000 to 1,499 mL diarrhea/ day
3: Maculopapular rash &gt; 50% of body surface; Bilirubin 6.1-15 mg/dL; 1,500 or more mL diarrhea/ day
4: Generalized erythroderma with bullous formation; Bilirubin &gt; 15 mg/dL; Severe abdominal pain with or without ileus
Overall Clinical Grade:
0: No Stage 1-4 of any organ
I: Stage 1-2 rash and no liver or gut involvement
II: Stage 3 rash, or Stage 1 liver involvement, or Stage 1 gut involvement
III: None to Stage 3 skin rash with Stage 2-3 liver involvement, or Stage 2-4 gut involvement
IV: Stage 4 skin rash, or Stage 4 liver involvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Rate of Chronic GVHD</measure>
    <time_frame>From the time of transplantation until the time of chronic GVHD onset, up to 1 year</time_frame>
    <description>Chronic Graft Versus Host Disease (GVHD) is assessed using the National Institutes of Health (NIH) consensus criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>100-day Treatment Related Mortality</measure>
    <time_frame>100 Days</time_frame>
    <description>The percentage of treatment related participant deaths within 100 days of receiving umbilical cord blood transplantation. All deaths in the absence of relapse of the primary malignancy will be considered treatment related mortality.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune Reconstitution - Median CD4 Count at 12 Months</measure>
    <time_frame>1 Year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse-free Survival</measure>
    <time_frame>2 years</time_frame>
    <description>The percentage of participants that have not died or had disease progression by two years. Relapse is defined by either morphological or cytogenetic evidence of the original malignancy consistent with pre-transplant features.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>2 years</time_frame>
    <description>The percentage of participants alive at two years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1 Year Relapse Rate</measure>
    <time_frame>1 year</time_frame>
    <description>The percentage of participants that relapsed within 12 months. Relapse is defined by either morphological or cytogenetic evidence of the original malignancy consistent with pre-transplant features.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Post-transplant Lymphoma</measure>
    <time_frame>2.5 years</time_frame>
    <description>The number of participants that were found to have lymphoma post-transplant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Thrombopoietin Levels After Transplant</measure>
    <time_frame>30 Days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Non-Hodgkin's Lymphoma</condition>
  <condition>Hodgkin's Lymphoma</condition>
  <condition>Multiple Myeloma</condition>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>Acute Myelogenous Leukemia</condition>
  <arm_group>
    <arm_group_label>Fludarabine/Melphalan/TBI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients receive same therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>30 mg/m2/day IV x 6 days</description>
    <arm_group_label>Fludarabine/Melphalan/TBI</arm_group_label>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>100 mg/m2/day IV x 1 day</description>
    <arm_group_label>Fludarabine/Melphalan/TBI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total Body Radiation</intervention_name>
    <description>200 cGy on Day 0</description>
    <arm_group_label>Fludarabine/Melphalan/TBI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cord Blood</intervention_name>
    <description>2 cord blood units IV</description>
    <arm_group_label>Fludarabine/Melphalan/TBI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hematologic malignancy for whom allogeneic stem cell transplantation is deemed
             clinically appropriate

          -  Appropriate candidate for reduced intensity regimen, according to the treating
             physician

          -  Lack of 6/6/ or 5/6 HLA-matched related, 8/8/ HLA-matched unrelated donor, or
             unrelated donor not available with a time frame necessary to perform a potentially
             curative stem cell transplant

          -  Able to comply with the requirements for care after allogeneic stem cell
             transplantation

        Exclusion Criteria:

          -  Cardiac disease: symptomatic congestive heart failure or evidence of left ventricular
             dysfunction

          -  Pulmonary disease: symptomatic chronic obstructive lung disease, symptomatic
             restrictive lung disease

          -  Renal disease

          -  Hepatic disease

          -  Neurologic disease: symptomatic leukoencephalopathy, active CNS malignancy or other
             neuropsychiatric abnormalities believed to preclude transplantation

          -  HIV-positive

          -  Uncontrolled infection

          -  Pregnant or breast-feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zachariah DeFilipp, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>August 2, 2011</study_first_submitted>
  <study_first_submitted_qc>August 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2011</study_first_posted>
  <results_first_submitted>September 14, 2018</results_first_submitted>
  <results_first_submitted_qc>October 24, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 21, 2018</results_first_posted>
  <last_update_submitted>December 29, 2018</last_update_submitted>
  <last_update_submitted_qc>December 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Zachariah Michael DeFilipp</investigator_full_name>
    <investigator_title>Hematology/Oncology</investigator_title>
  </responsible_party>
  <keyword>NHL</keyword>
  <keyword>lymphoma</keyword>
  <keyword>leukemia</keyword>
  <keyword>myelodysplastic disorder</keyword>
  <keyword>aplastic anemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Melphalan</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 6, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/63/NCT01408563/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Fludarabine/Melphalan/TBI</title>
          <description>All patients receive same therapy
Fludarabine: 30 mg/m2/day IV x 6 days
Melphalan: 100 mg/m2/day IV x 1 day
Total Body Radiation: 200 cGy on Day 0
Cord Blood: 2 cord blood units IV</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Transplant</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Ineligible after consent/ registration</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The two participants found to be ineligible after being consented and registered were excluded from the analysis.</population>
      <group_list>
        <group group_id="B1">
          <title>Fludarabine/Melphalan/TBI</title>
          <description>All patients receive same therapy
Fludarabine: 30 mg/m2/day IV x 6 days
Melphalan: 100 mg/m2/day IV x 1 day
Total Body Radiation: 200 cGy on Day 0
Cord Blood: 2 cord blood units IV</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="31"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57" lower_limit="21" upper_limit="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Performance Status</title>
          <description>Eastern Cooperative Oncology Group (ECOG) Performance Status:
0 - Asymptomatic (Fully active, able to carry on all predisease activities without restriction)
1 - Symptomatic but completely ambulatory (Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature. For example, light housework, office work)
2 - Symptomatic, &lt;50% in bed during the day (Ambulatory and capable of all self care but unable to carry out any work activities. Up and about more than 50% of waking hours)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>0</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Disease</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Acute Lymphoblastic Leukemia (ALL)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Acute Myeloid Leukemia (AML)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hodgkin's Disease (HD)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Myelodysplastic Syndromes (MDS)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Myeloproliferative Disorder (MPD)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-Hodgkin Lymphoma (NHL)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With a Clinically Significant Infection</title>
        <description>The one year significant infection rate (infections requiring medical intervention) after double umbilical cord blood transplant using a novel conditioning regimen of fludarabine/melphalan/low dose total body radiation. The data is shown as the number of significant infections participants experienced during the first year, measured from the start of treatment.</description>
        <time_frame>1 Year</time_frame>
        <population>The two participants found to be ineligible after being consented and registered were excluded from the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Fludarabine/Melphalan/TBI</title>
            <description>All patients receive same therapy
Fludarabine: 30 mg/m2/day IV x 6 days
Melphalan: 100 mg/m2/day IV x 1 day
Total Body Radiation: 200 cGy on Day 0
Cord Blood: 2 cord blood units IV</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Clinically Significant Infection</title>
          <description>The one year significant infection rate (infections requiring medical intervention) after double umbilical cord blood transplant using a novel conditioning regimen of fludarabine/melphalan/low dose total body radiation. The data is shown as the number of significant infections participants experienced during the first year, measured from the start of treatment.</description>
          <population>The two participants found to be ineligible after being consented and registered were excluded from the analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>0 Infections</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1 Infection</title>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2 Infections</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Time to Neutrophil Engraftment</title>
        <description>The median number of days measured from the time of transplantation, until the first documented neutrophil engraftment. neutrophil engraftment is defined as the first of 3 consecutive days of absolute neutrophil count &gt; 500 neutrophils per microliter of blood.</description>
        <time_frame>From the time of transplantation, until the time of neutrophil engraftment, median duration of 24 days</time_frame>
        <population>The two participants found to be ineligible after being consented and registered were excluded from the analysis. In addition to those two participants, the 8 participants that did not achieve engraftment were not included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Fludarabine/Melphalan/TBI</title>
            <description>All patients receive same therapy
Fludarabine: 30 mg/m2/day IV x 6 days
Melphalan: 100 mg/m2/day IV x 1 day
Total Body Radiation: 200 cGy on Day 0
Cord Blood: 2 cord blood units IV</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time to Neutrophil Engraftment</title>
          <description>The median number of days measured from the time of transplantation, until the first documented neutrophil engraftment. neutrophil engraftment is defined as the first of 3 consecutive days of absolute neutrophil count &gt; 500 neutrophils per microliter of blood.</description>
          <population>The two participants found to be ineligible after being consented and registered were excluded from the analysis. In addition to those two participants, the 8 participants that did not achieve engraftment were not included in the analysis.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24" lower_limit="1" upper_limit="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Time to Platelet Engraftment</title>
        <description>The time to platelet engraftment is measured from the time of transplantation until the time of first documented platelet engraftment. Platelet engraftment is defined as a platelet count ≥ 20,000/µL for three consecutive measurements over three or more days. The first of the three days will be designated the day of platelet engraftment. Subjects must not have had platelet transfusions during the preceding 3 days or in the following 7 days after the day of engraftment, unless the platelet transfusion is being given specifically to achieve a platelet threshold to allow an elective invasive procedure, such as a central catheter removal.</description>
        <time_frame>From the time of transplantation, until the time of platelet engraftment, median duration of 52 days</time_frame>
        <population>The two participants found to be ineligible after being consented and registered were excluded from the analysis. In addition to those two participants, the 10 participants that did not achieve engraftment were not included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Fludarabine/Melphalan/TBI</title>
            <description>All patients receive same therapy
Fludarabine: 30 mg/m2/day IV x 6 days
Melphalan: 100 mg/m2/day IV x 1 day
Total Body Radiation: 200 cGy on Day 0
Cord Blood: 2 cord blood units IV</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time to Platelet Engraftment</title>
          <description>The time to platelet engraftment is measured from the time of transplantation until the time of first documented platelet engraftment. Platelet engraftment is defined as a platelet count ≥ 20,000/µL for three consecutive measurements over three or more days. The first of the three days will be designated the day of platelet engraftment. Subjects must not have had platelet transfusions during the preceding 3 days or in the following 7 days after the day of engraftment, unless the platelet transfusion is being given specifically to achieve a platelet threshold to allow an elective invasive procedure, such as a central catheter removal.</description>
          <population>The two participants found to be ineligible after being consented and registered were excluded from the analysis. In addition to those two participants, the 10 participants that did not achieve engraftment were not included in the analysis.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52" lower_limit="21" upper_limit="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Primary Graft Failure</title>
        <description>Primary graft failure is defined as the failure to achieve an absolute neutrophil count (ANC) &gt;500/ µL by day 42, in the absence of relapse.</description>
        <time_frame>From the time of transplantation until 42 days post transplantation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fludarabine/Melphalan/TBI</title>
            <description>All patients receive same therapy
Fludarabine: 30 mg/m2/day IV x 6 days
Melphalan: 100 mg/m2/day IV x 1 day
Total Body Radiation: 200 cGy on Day 0
Cord Blood: 2 cord blood units IV</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Primary Graft Failure</title>
          <description>Primary graft failure is defined as the failure to achieve an absolute neutrophil count (ANC) &gt;500/ µL by day 42, in the absence of relapse.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rates of Grade II-IV and Grade III-IV Acute Graft Versus Host Disease (GVHD) at 100 Days</title>
        <description>Acute GVHD is assessed using Consensus Criteria:
Organ Classifications:
0: No rash due to GVHD; Bilirubin &lt; 2 mg/dL; &lt; 500 mL diarrhea/ day
1: Maculopapular rash &lt; 25% of body surface; Bilirubin 2-3 mg/dL; 500 to 999 mL diarrhea/ day or persistent nausea with histologic evidence of GVHD in stomach/ duodenum
2: Maculopapular rash 25-50% of body surface; Bilirubin 3.1-6 mg/dL; 1,000 to 1,499 mL diarrhea/ day
3: Maculopapular rash &gt; 50% of body surface; Bilirubin 6.1-15 mg/dL; 1,500 or more mL diarrhea/ day
4: Generalized erythroderma with bullous formation; Bilirubin &gt; 15 mg/dL; Severe abdominal pain with or without ileus
Overall Clinical Grade:
0: No Stage 1-4 of any organ
I: Stage 1-2 rash and no liver or gut involvement
II: Stage 3 rash, or Stage 1 liver involvement, or Stage 1 gut involvement
III: None to Stage 3 skin rash with Stage 2-3 liver involvement, or Stage 2-4 gut involvement
IV: Stage 4 skin rash, or Stage 4 liver involvement</description>
        <time_frame>100 Days</time_frame>
        <population>The two participants found to be ineligible after being consented and registered were excluded from the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Fludarabine/Melphalan/TBI</title>
            <description>All patients receive same therapy
Fludarabine: 30 mg/m2/day IV x 6 days
Melphalan: 100 mg/m2/day IV x 1 day
Total Body Radiation: 200 cGy on Day 0
Cord Blood: 2 cord blood units IV</description>
          </group>
        </group_list>
        <measure>
          <title>Rates of Grade II-IV and Grade III-IV Acute Graft Versus Host Disease (GVHD) at 100 Days</title>
          <description>Acute GVHD is assessed using Consensus Criteria:
Organ Classifications:
0: No rash due to GVHD; Bilirubin &lt; 2 mg/dL; &lt; 500 mL diarrhea/ day
1: Maculopapular rash &lt; 25% of body surface; Bilirubin 2-3 mg/dL; 500 to 999 mL diarrhea/ day or persistent nausea with histologic evidence of GVHD in stomach/ duodenum
2: Maculopapular rash 25-50% of body surface; Bilirubin 3.1-6 mg/dL; 1,000 to 1,499 mL diarrhea/ day
3: Maculopapular rash &gt; 50% of body surface; Bilirubin 6.1-15 mg/dL; 1,500 or more mL diarrhea/ day
4: Generalized erythroderma with bullous formation; Bilirubin &gt; 15 mg/dL; Severe abdominal pain with or without ileus
Overall Clinical Grade:
0: No Stage 1-4 of any organ
I: Stage 1-2 rash and no liver or gut involvement
II: Stage 3 rash, or Stage 1 liver involvement, or Stage 1 gut involvement
III: None to Stage 3 skin rash with Stage 2-3 liver involvement, or Stage 2-4 gut involvement
IV: Stage 4 skin rash, or Stage 4 liver involvement</description>
          <population>The two participants found to be ineligible after being consented and registered were excluded from the analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" lower_limit="5.7" upper_limit="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Rate of Chronic GVHD</title>
        <description>Chronic Graft Versus Host Disease (GVHD) is assessed using the National Institutes of Health (NIH) consensus criteria.</description>
        <time_frame>From the time of transplantation until the time of chronic GVHD onset, up to 1 year</time_frame>
        <population>The two participants found to be ineligible after being consented and registered were excluded from the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Fludarabine/Melphalan/TBI</title>
            <description>All patients receive same therapy
Fludarabine: 30 mg/m2/day IV x 6 days
Melphalan: 100 mg/m2/day IV x 1 day
Total Body Radiation: 200 cGy on Day 0
Cord Blood: 2 cord blood units IV</description>
          </group>
        </group_list>
        <measure>
          <title>The Rate of Chronic GVHD</title>
          <description>Chronic Graft Versus Host Disease (GVHD) is assessed using the National Institutes of Health (NIH) consensus criteria.</description>
          <population>The two participants found to be ineligible after being consented and registered were excluded from the analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21" lower_limit="8.1" upper_limit="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>100-day Treatment Related Mortality</title>
        <description>The percentage of treatment related participant deaths within 100 days of receiving umbilical cord blood transplantation. All deaths in the absence of relapse of the primary malignancy will be considered treatment related mortality.</description>
        <time_frame>100 Days</time_frame>
        <population>The two participants found to be ineligible after being consented and registered were excluded from the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Fludarabine/Melphalan/TBI</title>
            <description>All patients receive same therapy
Fludarabine: 30 mg/m2/day IV x 6 days
Melphalan: 100 mg/m2/day IV x 1 day
Total Body Radiation: 200 cGy on Day 0
Cord Blood: 2 cord blood units IV</description>
          </group>
        </group_list>
        <measure>
          <title>100-day Treatment Related Mortality</title>
          <description>The percentage of treatment related participant deaths within 100 days of receiving umbilical cord blood transplantation. All deaths in the absence of relapse of the primary malignancy will be considered treatment related mortality.</description>
          <population>The two participants found to be ineligible after being consented and registered were excluded from the analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.7" lower_limit="2.4" upper_limit="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immune Reconstitution - Median CD4 Count at 12 Months</title>
        <time_frame>1 Year</time_frame>
        <population>CD4 counts were only available for 11 participants at the 12 months time point</population>
        <group_list>
          <group group_id="O1">
            <title>Fludarabine/Melphalan/TBI</title>
            <description>All patients receive same therapy
Fludarabine: 30 mg/m2/day IV x 6 days
Melphalan: 100 mg/m2/day IV x 1 day
Total Body Radiation: 200 cGy on Day 0
Cord Blood: 2 cord blood units IV</description>
          </group>
        </group_list>
        <measure>
          <title>Immune Reconstitution - Median CD4 Count at 12 Months</title>
          <population>CD4 counts were only available for 11 participants at the 12 months time point</population>
          <units>cells/mm3</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="362.4" lower_limit="125.3" upper_limit="1157.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relapse-free Survival</title>
        <description>The percentage of participants that have not died or had disease progression by two years. Relapse is defined by either morphological or cytogenetic evidence of the original malignancy consistent with pre-transplant features.</description>
        <time_frame>2 years</time_frame>
        <population>The two participants found to be ineligible after being consented and registered were excluded from the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Fludarabine/Melphalan/TBI</title>
            <description>All patients receive same therapy
Fludarabine: 30 mg/m2/day IV x 6 days
Melphalan: 100 mg/m2/day IV x 1 day
Total Body Radiation: 200 cGy on Day 0
Cord Blood: 2 cord blood units IV</description>
          </group>
        </group_list>
        <measure>
          <title>Relapse-free Survival</title>
          <description>The percentage of participants that have not died or had disease progression by two years. Relapse is defined by either morphological or cytogenetic evidence of the original malignancy consistent with pre-transplant features.</description>
          <population>The two participants found to be ineligible after being consented and registered were excluded from the analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49" lower_limit="30" upper_limit="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>The percentage of participants alive at two years</description>
        <time_frame>2 years</time_frame>
        <population>The two participants found to be ineligible after being consented and registered were excluded from the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Fludarabine/Melphalan/TBI</title>
            <description>All patients receive same therapy
Fludarabine: 30 mg/m2/day IV x 6 days
Melphalan: 100 mg/m2/day IV x 1 day
Total Body Radiation: 200 cGy on Day 0
Cord Blood: 2 cord blood units IV</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>The percentage of participants alive at two years</description>
          <population>The two participants found to be ineligible after being consented and registered were excluded from the analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55" lower_limit="35" upper_limit="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>1 Year Relapse Rate</title>
        <description>The percentage of participants that relapsed within 12 months. Relapse is defined by either morphological or cytogenetic evidence of the original malignancy consistent with pre-transplant features.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fludarabine/Melphalan/TBI</title>
            <description>All patients receive same therapy
Fludarabine: 30 mg/m2/day IV x 6 days
Melphalan: 100 mg/m2/day IV x 1 day
Total Body Radiation: 200 cGy on Day 0
Cord Blood: 2 cord blood units IV</description>
          </group>
        </group_list>
        <measure>
          <title>1 Year Relapse Rate</title>
          <description>The percentage of participants that relapsed within 12 months. Relapse is defined by either morphological or cytogenetic evidence of the original malignancy consistent with pre-transplant features.</description>
          <units>percentage</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" lower_limit="4" upper_limit="27.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Post-transplant Lymphoma</title>
        <description>The number of participants that were found to have lymphoma post-transplant.</description>
        <time_frame>2.5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fludarabine/Melphalan/TBI</title>
            <description>All patients receive same therapy
Fludarabine: 30 mg/m2/day IV x 6 days
Melphalan: 100 mg/m2/day IV x 1 day
Total Body Radiation: 200 cGy on Day 0
Cord Blood: 2 cord blood units IV</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Post-transplant Lymphoma</title>
          <description>The number of participants that were found to have lymphoma post-transplant.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Thrombopoietin Levels After Transplant</title>
        <time_frame>30 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fludarabine/Melphalan/TBI</title>
            <description>All patients receive same therapy
Fludarabine: 30 mg/m2/day IV x 6 days
Melphalan: 100 mg/m2/day IV x 1 day
Total Body Radiation: 200 cGy on Day 0
Cord Blood: 2 cord blood units IV</description>
          </group>
        </group_list>
        <measure>
          <title>Median Thrombopoietin Levels After Transplant</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2500" lower_limit="320" upper_limit="4000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events are assessed from the start of treatment until the end of follow-up, up to two years.</time_frame>
      <desc>The two participants found to be ineligible after being consented and registered were excluded from the analysis.</desc>
      <group_list>
        <group group_id="E1">
          <title>Fludarabine/Melphalan/TBI</title>
          <description>All patients receive same therapy
Fludarabine: 30 mg/m2/day IV x 6 days
Melphalan: 100 mg/m2/day IV x 1 day
Total Body Radiation: 200 cGy on Day 0
Cord Blood: 2 cord blood units IV</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood and lymphatic system disorders - Other, specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Rectal perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>General disorders and administration site conditions - Other, specify</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Encephalitis infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Infections and infestations - Other, specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Edema cerebral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Reversible posterior leukoencephalopathy syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Blood and lymphatic system disorders - Other, specify</sub_title>
                <counts group_id="E1" events="21" subjects_affected="6" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="11" subjects_affected="4" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="15" subjects_affected="12" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" events="14" subjects_affected="7" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="18" subjects_affected="9" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Encephalitis infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="16" subjects_affected="6" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Acidosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Hyperuricemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="17" subjects_affected="7" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="12" subjects_affected="4" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Zachariah DeFilipp</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617-643-3944</phone>
      <email>ZDEFILIPP@mgh.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

